Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens prescription method aims to sharpen your sight

NCT ID NCT07168564

Symptom relief Sponsor: Essilor International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether glasses made with a new prescription method (Essilor AVA) give better vision and comfort than standard glasses. About 120 adults with common vision problems wore both types of lenses for two weeks each. The goal was to see which people preferred and if the new method improved quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Sep 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age between 18 y/o and 70 2. Accepted and signed the consent form 3. Agree to participate in the scheduled visits 4. Best-corrected visual acuity by manifest refraction of +0.10 log MAR (20/25 Snellen) or better in each eye 5. Spherical Equivalent Refractive Error between -10.00 and 10.00 D 6. Possess current wearable and visually functional eyeglasses 7. Agree to wear the assigned frames fitted with the provided lenses for a minimum of 14 days, during 6h/day, equivalent to 42 hours of wearing a week. 8. No binocular vision issues 9. No cataract, grade 2 or greater Presbyope subjects: To be eligible for the presbyopic group, individuals need to be (half of the analyzed population): 10. 35-70 years of age, inclusive 11. Currently wearing and adapted to progressive addition lenses Exclusion Criteria: 1. Less than 18 years or greater than 70 years of age 2. Does not wear spectacles at least 6 hours/day 3. Does not have a wearable pair of glasses with a prescription ≤2 years old 4. Currently or formerly a licensed optometrist, optician, or ophthalmic technician trained in refraction

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ametropia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ametropia Refractive error

Contacts and locations

Locations

  • Clinical Optics Research Lab @ Borish Center for Ophthalmic Research Indiana University School of Optometry Indiana University

    Bloomington, Indiana, 47405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.